Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
Date:3/7/2013

ble non-small cell lung cancer. OGX-427 is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial completion and design, statements regarding the potential benefits and potential development of our product candidates and statements regarding our expected financial results and expected cash requirements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product, the risk that our cash resources are insufficient to fund our planned activities for the time period expected and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update the forward-looking statements contained herein or t
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
2. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
3. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014  Lockton Dunning Benefits, the ... announced the addition of Vice President Kim ... Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... experience to the position.  Most recently, she worked ... Diplomat Specialty Pharmacy, where she has held various ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/24/2014)... , Dec. 23, 2014  Endo Pharmaceuticals Inc., ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, Inc. ... have submitted a New Drug Application (NDA) for Buprenorphine ... Administration (FDA).  Buprenorphine HCl Buccal Film is under development ... daily, around-the-clock, long-term opioid treatment and for which alternative ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... LifeVantage Corporation (OTCBB: LFVN), makers of ... that Douglas C. Robinson, the Company,s President and Chief ... Science Officer, will be presenting at the Rodman & ... September 11-13, 2011, at the Waldorf Astoria in New ...
... TALLAHASSEE, Fla., Aug. 31, 2011 A recent study ... dispels the myth that physicians, offices use prostate ... The article, "Utilization Trends in Prostate ... utilization of both surgical and radiation therapy for management ...
Cached Medicine Technology:LifeVantage to Present at Rodman & Renshaw Annual Global Investment Conference 2Study Explores Utilization Trends for Prostate Cancer Treatments 2
(Date:12/26/2014)... Texas (PRWEB) December 26, 2014 Yisrayl Hawkins, ... written an open letter in light of the Ferguson, Missouri ... history of civil unrest and explains why it has only ... reason mankind was even created. He says there is a ... detail. Yisrayl also says there is a set of rules, ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the ... for 2014. The awards program, created in 2000, is ... in the country. The program is a public/private partnership ... and Economic Development, the Pennsylvania State Council of the ... Business Journal. , Charlie Wilson, Vice President ...
(Date:12/25/2014)... 26, 2014 The click ... beauty, strength and durability. Today, the business announces ... is valid until Jan. 30, 2015. , Click ... traditional hardwood. BambooFlooringChina.com is a well-known brand in ... worldwide to find a reliable bamboo flooring supplier. ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... 25, 2014 Helen Harris’ RP (Retinitis ... Hills, California after an 8 year battle with breast ... Eve evening in her home in Woodland Hills California ... cancer. , As the founder and ... she pioneered and championed many of today's greatest breakthroughs ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... imaging (MRI) shows that childhood stress such as ... with genetic factors, can result in structural brain ... depression. The study led by scientists at Trinity ... international scientific journal, Neuropsychopharmacology . Commenting on ...
... chemotherapy followed by radiation to preserve their larynx have ... experienced no eating or swallowing problems, according to a ... Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ... is the current standard treatment for patients with cancer ...
... maximal standardized uptake value (called SUVmax) measured from ... in head and neck squamous cell carcinoma patients ... survival, overall survival and disease-free survival, while pretreatment ... metastasis, according to a study presented at the ...
... than Canada, study finds , THURSDAY, Feb. 25 (HealthDay ... among women, explain why arthritis is more common in ... new study. , Researchers at the Toronto Western Research ... that the prevalence of arthritis in the United States ...
... WellNet ... performance management strategies are the way to more effectively control healthcare costs across the ... Bethesda, ... Healthcare Performance Management (HPM) Institute, WellNet today expressed its support for -- and agreement ...
... TeraMedica ... its revolutionary Evercore® – Enterprise Clinical Suite software system, now available on Red Hat ... ... a leading medical informatics company, has launched a new enterprise platform for its revolutionary ...
Cached Medicine News:Health News:Childhood stress such as abuse or emotional neglect can result in structural brain changes 2Health News:Pretreatment SUV associated with head and neck cancer treatment outcomes, may help decide treatment plans 2Health News:WellNet Supports HPM Institute Director in Calling for More Active Enterprise Involvement in Managing Healthcare Quality and Costs 2Health News:TeraMedica Launches Evercore – Clinical Enterprise Suite 5.0 Now on Linux 2
... The AutoIncubator 96 can incubate and shake up ... 96 samples at a time. This new ... enzyme reactions, such as Proteinase K digestion. ... process by preparing your samples with our AutoIncubator ...
... incubators,Two refrigerated incubators that are ... life cycle,testing. Microprocessor controlled heating ... display. High/low audible and visual ... internal chamber safety thermostat,provides over-temperature ...
Inquire...
Inquire...
Medicine Products: